Cargando…
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
The FIP1L1-PDGFRA rearrangement results in constitutive activation of the tyrosine kinase PDGFRA. Neoplasms harboring this rearrangement are responsive to imatinib mesylate at doses much lower than those recommended for the treatment of chronic myelogenous leukemia. Only a single report has describe...
Autores principales: | Shah, Shilpan, Loghavi, Sanam, Garcia-Manero, Guillermo, Khoury, Joseph D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994268/ https://www.ncbi.nlm.nih.gov/pubmed/24669761 http://dx.doi.org/10.1186/1756-8722-7-26 |
Ejemplares similares
-
Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement
por: Kim, Tae Hee, et al.
Publicado: (2016) -
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib
por: Kim, Dae Sik, et al.
Publicado: (2018) -
Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China
por: Qu, Shi-Qiang, et al.
Publicado: (2016) -
P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2023) -
Pruritus as a Presenting Symptom of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia
por: Abu-Tineh, Mohammad, et al.
Publicado: (2021)